Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Basilea Pharmaceutica has commenced a dose-escalation, open-label Phase I trial of its intravenous anti cancer medication - BAL10155.
Subscribe to our email newsletter
In the study, the company will assess tolerability, safety and phamacokinetics of BAL101553 to determine the dose and administration schedule for Phase II trials.
Previosly, BAL101553, a novel microtubule-targeting agent, has showed anti-cancer activity in many drug-resistant tumor models.
Basilea CEO Anthony Man said BAL101553 is a novel small-molecule drug active against a well-validated cancer cell target and showing broad anti- tumor activity in preclinical models.